← All trials
NCT05463965
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2022
- Primary completion
- Feb 28, 2023
- Completion date
- Jul 30, 2023
- First posted
- Jul 19, 2022
- Last posted
- Sep 13, 2022
- Enrollment
- 600
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GaldermaLead sponsor
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.